Prescribing trends of glaucoma medication in Korea from 2007 to 2020: A nationwide population-based study
PLOS ONE · 11.07.2024 · 19 (7) · e0305619
DOI: 10.1371/journal.pone.0305619 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 11.07.2024. Verfasst von Kyeong Ik Na und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Glaucoma, Ophthalmic Solutions, Drug Prescriptions. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kangdong Sacred Heart Hospital, Hallym University.
Abstract (Originalsprache)
Purpose
Investigating long-term trends in glaucoma medication.
Methods
All patients diagnosed with glaucoma and prescribed glaucoma eye drops between 2007 and 2020 in Korea’s Health Insurance Review and Assessment Service database participated in this study. A weight was assigned to each prescription using the reciprocal of the total number of prescriptions received by the individual in that year. The number of patients who received each type of glaucoma eye drop prescription was calculated by summing the weights for each year.
Results
During the study period, prostaglandin analog eye drop monotherapy was the most frequently given type of glaucoma eye drop prescription. Until 2008, the second most frequently given type of glaucoma eye drop prescription was beta blocker eye drop monotherapy; thereafter, it changed to carbonic anhydrase inhibitor/beta blocker fixed-combination eye drop monotherapy. The prescription proportion of single-ingredient glaucoma eye drops decreased (-1.290%/year, P < 0.001), whereas that of fixed-combination glaucoma eye drops increased (1.291%/year, P < 0.001). The number of glaucoma eye drops prescribed per patient remained constant (-0.00030/year, P = 0.167) with an average of 1.302, while the number of active ingredients prescribed per patient increased (0.01737/year, P < 0.001) from 1.659 in 2007 to 1.896 in 2020.
Conclusion
Over 14 years, there was no change in the number of glaucoma eye drops prescribed to individual patients in Korea. However, the number of active ingredients prescribed increased owing to the increased prescription of fixed-combination eye drops. The current trends in glaucoma medication are expected to help establish future treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.
- Department of Ophthalmology, Hanyang University Seoul Hospital, Hanyang University College of Medicine, Seoul, Korea.
ORCID-Profile: Kyeong Ik Na, Sung Pyo Park
Förderung
- Kangdong Sacred Heart Hospital, Hallym University
Zitieren
APA
Na, K. I., Lee, W. J., Choi, Y. J., & Park, S. P. (2024). Prescribing trends of glaucoma medication in Korea from 2007 to 2020: A nationwide population-based study. PLOS ONE, 19(7), e0305619. https://doi.org/10.1371/journal.pone.0305619
Vancouver
Na KI, Lee WJ, Choi YJ, Park SP. Prescribing trends of glaucoma medication in Korea from 2007 to 2020: A nationwide population-based study. PLOS ONE. 2024;19(7):e0305619. doi:10.1371/journal.pone.0305619
BibTeX
@article{Na2024,
author = {Na, Kyeong Ik and Lee, Won June and Choi, Youn Joo and Park, Sung Pyo},
title = {Prescribing trends of glaucoma medication in Korea from 2007 to 2020: A nationwide population-based study},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {7},
pages = {e0305619},
doi = {10.1371/journal.pone.0305619}
}
EUVIMED